TAVI Procedure Accesses: Our Experience and Comparison of Transapical Versus Transfemoral Routes

Keywords: transcatheter aortic valve replacement, aortic valve stenosis, TAVI, acquired heart defects, transapical access, transfemoral access

Abstract

There is no denying the fact that surgical aortic valve replacement has been considered as the “gold standard” of treatment for patients with aortic stenosis (AS). However, approaches are changing. A particularly influential event was the first successful transcatheter aortic valve implantation (TAVI) from an antegrade transseptal approach in 2002.

The aim. To evaluate the results of TAVI performed using transapical and transfemoral access in patients over 60 years of age with severe AS.

Materials and methods. This single-center study was performed at the Ukrainian Children’s Cardiac Center in the period from 2016 to 2024. The study included 105 consecutive patients with a confirmed diagnosis of severe AS. All the patients met eligibility criteria, received a full package of basic and additional examinations and, based on the decision of the heart team led by a cardiac surgeon, were verified for the TAVI procedure from the appropriate access: transfemoral access in group 1 (n = 54 patients), transapical access in group 2 (n = 51 patients). Patients who had previously undergone aortic valve replacement were excluded from the study.

Results. All the patients were verified as high surgical risk patients according to the STS Adult Cardiac Surgery Risk Calculator, EuroSCORE II, ASA scales. Intraoperative mortality was 0.95% (n = 1). The postoperative period of hospital stay (from the time of operation to discharge) was 11.13 ± 10.45 days (from 3 to 54) in group 1 and 12.65 ± 11.68 days (from 0 to 71) in group 2. The procedure was performed under general anesthesia in both groups. Duration of the operation was 147.59 ± 113.46 minutes (from 110 to 810) in group 1, and 168.31 ± 93.61 minutes (from 76 to 690) in group 2. Early outcomes, assessed by echocardiography and aortography, were satisfactory in all the patients. In group 1, minimal paravalvular insufficiency was detected in 92.6% (n = 50), moderate paravalvular insufficiency was observed in 7.4% (n = 7) patients. In group 2, minimal deficiency was found in 90.2% (n = 46), moderate in 9.8% (n = 5) patients.

Conclusions. Early and long-term postoperative outcomes were satisfactory in both groups. There was no statistically significant difference between the groups in the level of complications. However, the pattern of complications differed between the groups: the transfemoral group had a lower rate of postoperative bleeding and cerebrovascular disorders, while the transapical group had a lower rate of pacemaker implantation and prosthesis repositioning.

References

  1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al.; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. https://doi.org/10.1093/eurheartj/ehab395
  2. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e35-e71. https://doi.org/10.1161/CIR.0000000000000932
  3. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al.; PARTNER Trial Investigators. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010;363(17):1597-1607. https://doi.org/10.1056/NEJMoa1008232
  4. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description. Circulation. 2002;106(24):3006-3008. https://doi.org/10.1161/01.cir.0000047200.36165.b8
  5. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al.; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-2791. https://doi.org/10.1093/eurheartj/ehx391
  6. Gardner-Hilbert EF, Gómez-Sánchez M, Lumbreras-Márquez MI, Díaz-Moreno I. Incidence of Clinical Outcomes in Minimally Invasive Valvular Surgery at the Ignacio Chávez National Institute of Cardiology. Cureus. 2024;16(9):e69859. https://doi.org/10.7759/cureus.69859
  7. Webb JG, Blanke P, Meier D, Sathananthan J, Lauck S, Chatfield AG, et al. TAVI in 2022: Remaining issues and future direction. Arch Cardiovasc Dis. 2022;115(4):235-242. https://doi.org/10.1016/j.acvd.2022.04.001
  8. Wolfes J, Alba FT, Kaleschke G, Vormbrock J, Reinke F, Ellermann C, et al. Pacemaker Implantation for Low-Grade Conduction Abnormalities After Balloon-Expandable Transcatheter Aortic Valve Implantation. Clin Cardiol. 2024;47(11):e70028. https://doi.org/10.1002/clc.70028
  9. Chamoun N, Jdaidani J, Iskandarani DZ, Ghalayini S, Zgheib A, Khoury A, et al. Short-Term Clinical Outcomes of Transcatheter Aortic Valve Replacement in a Developing Country. Cureus. 2024;16(4):e58334. https://doi.org/10.7759/cureus.58334
  10. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al.; Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1706-1715. https://doi.org/10.1056/NEJMoa1816885
  11. Ye J, Cheung A, Lichtenstein SV, Carere RG, Thompson CR, Pasupati S, et al. Transapical aortic valve implantation in humans. J Thorac Cardiovasc Surg. 2006;131(5):1194-1196. https://doi.org/10.1016/j.jtcvs.2006.01.026
  12. Marushko YY, Rudenko NM, Mankovskyi GB, Revenko KA, Yemets IM. [Transcatheter aortic valve implantation in patients of high surgical risk: world experience and perspective of usage in Ukraine]. Ukrainian Journal of Cardiology. 2016;(1):12-20. Ukrainian.
  13. Aksenov EV, Berestovenko VS, Panichkin YV, Vitovskiy RM, Humeniuk BN, Kravchuk BB, et al. [First experience of endovascular endoprothesis aortic valve]. Yearbook of Scientific Papers of the Association of cardiovascular surgeons of Ukraine. 2013;(21):27-31. Russian.
Published
2024-12-27
How to Cite
1.
Yemets GI, Horbatiuk VI, Maksymenko AV. TAVI Procedure Accesses: Our Experience and Comparison of Transapical Versus Transfemoral Routes. ujcvs [Internet]. 2024Dec.27 [cited 2025Jan.21];32(4):96-101. Available from: https://cvs.org.ua/index.php/ujcvs/article/view/691